NCT02744820 - Multiple Ascending Dose Study of GMC-252-L-Lys Salt in Healthy Subjects and Type 2 Diabetics | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions

HealthyType 2 Diabetes Mellitus

Interventions

DRUG

GMC-252-L-Lysine Salt

1 dose by oral route, once a day, 28 days

OTHER

Placebo

Matching doses by oral route, once a day, 28 days

Trial Locations (2)

BioKinetic Europe Ltd., Belfast

Simbec Research Ltd, Merthyr Tydfil